Mothers (Tokyo Stock Exchange)

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe

Retrieved on:

星期一, 五月 15, 2023

Code, COVID-19, Patent, MD, Patient, Risk, Tokyo Stock Exchange, Bacteria, MPH, Pneumonia, Mothers (Tokyo Stock Exchange), Respiratory failure, Vaccine, Doctor of Philosophy

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than February 2039.

Key Points:

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than February 2039.
The allowed claims cover MN-166 (ibudilast) as a monotherapy in a patient diagnosed with or suffering from a microorganism infection.
The allowed claims cover a microorganism infection caused by a virus, bacteria, fungus, or any combination of two or more thereof.
We believe this patent broadly covers microorganism infection and will substantially increase the potential value of MN-166 as it further strengthens and expands our patent portfolio.”

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada

Retrieved on:

星期一, 五月 1, 2023

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2035.

Key Points:

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2035.
The allowed claims cover MN-001 (tipelukast) for the treatment of a patient diagnosed with advanced NASH.
In addition, the allowed claims cover MN-001 (tipelukast) for reducing hepatic fibrosis and hepatic scarring in a patient with advanced NASH.
The U.S. Patent and Trademark Office previously granted a patent which covers MN-001 and MN-002 for advanced NASH with fibrosis and similar patents were granted in Japan and Korea.”

MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Retrieved on:

星期四, 三月 9, 2023

Code, MCM, Mothers (Tokyo Stock Exchange), Biomedical Advanced Research and Development Authority, Tokyo Stock Exchange, Development, Administration, Acute respiratory distress syndrome, ASPR, BARDA, Human services, White lung, Chlorine, United States Department of Health and Human Services, ALI, Rare-earth element, Medical device

LA JOLLA, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).

Key Points:

LA JOLLA, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
The contract was amended to extend the period of performance until May 31, 2023.
This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50121C00022.

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

Retrieved on:

星期一, 二月 20, 2023

MN-166-GBM-1201; NCT03782415) at the 20th Annual World Congress of SBMT (Society for Brain Mapping and Therapeutics) held on February 16 - 19, 2023, in Los Angeles, CA.

Key Points:

MN-166-GBM-1201; NCT03782415) at the 20th Annual World Congress of SBMT (Society for Brain Mapping and Therapeutics) held on February 16 - 19, 2023, in Los Angeles, CA.
This tumor analysis study was a collaborative effort between MediciNova, Dr. Patrick Wen (Dana- Farber Cancer Institute), and Dr. Lathia (Cleveland Clinic Foundation).
Immunohistochemistry was performed on resected tumor tissue to evaluate MIF (macrophage migration inhibitory factor), pERK, Ki67, CD3, CD11b, and CD74.
Recently, we have completed study enrollment with MN-166-GBM-1201 study and look forward to the upcoming data analysis with more tissue samples.”

MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

Retrieved on:

星期三, 二月 8, 2023

Safety, Tokyo Stock Exchange, COVID-19, Health Canada, Quality of life, University Health Network, Mothers (Tokyo Stock Exchange), Long, Code, Patient, Clinical trial, Pharmaceutical industry, Long COVID

The trial, entitled REcovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine, or “RECLAIM,” is a collaboration between MediciNova and the University Health Network, the largest hospital-based research program in Canada.

Key Points:

The trial, entitled REcovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine, or “RECLAIM,” is a collaboration between MediciNova and the University Health Network, the largest hospital-based research program in Canada.
MediciNova will supply the study drug and will provide regulatory and safety follow-up support.
D, M.P.H., Chief Medical Officer, MediciNova, Inc., commented, “Since COVID-19 became a global health threat, multiple vaccines and treatment options became available, yet not many treatment options have been evaluated in COVID-19 sequelae, so-called Long COVID.
We are very excited about the initiation of this multi-arm Phase 2/3 trial to evaluate MN-166 as a drug candidate for Long COVID.”

MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

Retrieved on:

星期一, 一月 30, 2023

Psychiatry, UCLA, AUD, MD, Tokyo Stock Exchange, National Institute on Alcohol Abuse and Alcoholism, Principal, Mothers (Tokyo Stock Exchange), NIH, MPH, Code, NIAAA, Clinical trial, ABPP, University, Pharmaceutical industry, Psychology, Doctor of Philosophy

This clinical trial was funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA).

Key Points:

This clinical trial was funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
The clinical trial evaluated MN-166 (ibudilast) as a potential treatment to decrease alcohol consumption in treatment-seeking individuals diagnosed with AUD.
MediciNova provided drug supply and regulatory support for the clinical trial.
Lara Ray, PhD, Principal Investigator of the study, commented, “We have completed enrollment and are conducting follow-up on the last of the participants.

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma

Retrieved on:

星期四, 一月 12, 2023

This Phase 1/2 clinical trial was divided into a dose-escalation phase (Part 1) followed by a fixed-dose phase (Part 2).

Key Points:

This Phase 1/2 clinical trial was divided into a dose-escalation phase (Part 1) followed by a fixed-dose phase (Part 2).
Part 2 will evaluate the efficacy of MN-166 (ibudilast) and TMZ combination treatment.
We evaluated the correlation of MN-166 and TMZ combination therapy to clinical outcomes and tumor tissue analysis findings.
Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc., commented, "We have completed enrollment and are actively treating the remaining patients in Part 2 of the trial.

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

Retrieved on:

星期三, 一月 11, 2023

Intellectual property, Code, Canadian Intellectual Property Office, Capsule, Tablet, Scleroderma, Patent, Hydroxyproline, Mothers (Tokyo Stock Exchange), Tokyo Stock Exchange, Pharmaceutical industry

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than June 2035.

Key Points:

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than June 2035.
The allowed claims cover the use of MN-001 (tipelukast) or MN-002 for treating scleroderma and/or systemic sclerosis and for reducing and/or inhibiting elevated hydroxyproline levels in scleroderma/systemic sclerosis.
The allowed claims cover oral administration including liquid and solid dosage forms (tablets or capsules).
D., M.P.H., Chief Medical Officer, MediciNova, Inc., commented, “This new patent approval is based on positive results in a systemic sclerosis animal model study conducted previously.

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil

Retrieved on:

星期二, 一月 10, 2023

MPH, Hypertriglyceridemia, Hypercholesterolemia, NAFLD, Patent, Prediabetes, HTG, Code, Safety, LDL, Patient, Mothers (Tokyo Stock Exchange), Type 2 diabetes, Tokyo Stock Exchange, NASH, T2DM, Pharmaceutical industry, Hyperlipidemia

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034.

Key Points:

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034.
Ph.D., MPH., Chief Medical Officer, MediciNova, Inc., commented, “We are very pleased to receive notice that this new patent will be granted.
As we already have patents covering similar indications in the U.S., Canada, Europe, Japan, China, and Korea, we believe this additional patent in Brazil could increase the potential value of MN-001.
A trial to evaluate the efficacy and safety of MN-001 in patients with T2DM, NAFLD, and HTG is currently ongoing.”

MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)

Retrieved on:

星期四, 一月 5, 2023

Mothers (Tokyo Stock Exchange), Food, Acute respiratory distress syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tokyo Stock Exchange, AES, Sepsis, Cytokine release syndrome, Patient, Inflammation, HV, FDA, Code, Pharmaceutical industry

The trial results yielded encouraging findings as MN-166 (ibudilast) was delivered intravenously to HV with a favorable safety profile and was well tolerated.

Key Points:

The trial results yielded encouraging findings as MN-166 (ibudilast) was delivered intravenously to HV with a favorable safety profile and was well tolerated.
There were no concerning adverse events (AEs), all reported AEs were mild, all study drug-related AEs were mild, and none of the AEs were unexpected.
This IV formulation of MN-166 (ibudilast) is being developed for inflammatory disorders, specifically prevention of acute respiratory distress syndrome (ARDS), sepsis, and cytokine release syndrome.
A parenteral formulation will expand the clinical utility of MN-166 by enabling the treatment of indications for which the oral formulation is not suitable.